Brought to you by 
Concert licenses deuterated version of dextromethorphan to Avanir
16 Nov 2015
Executive Summary
Drug discovery company Concert Pharmaceuticals Inc. has licensed Avanir Pharmaceuticals Inc. (CNS and viral diseases) exclusive worldwide rights to multiple versions of dextromethorphan analogs that incorporate deuterium (d-DM). The agreement includes Concert’s CTP786 (formerly C10003), in preclinical studies for pain and pseudobulbar affect (PBA; sudden outbursts of uncontrollable emotional displays).
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Technologies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Concert licenses deuterated version of dextromethorphan to Avanir
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice